HLN (Haleon) Valuation Rank


HLN Haleon PLC HLN
70 GF Score
Price $9.82
GF Value $9.81
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Haleon Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Haleon Valuation Rank Related Terms

HLN
70GF Score
Haleon PLC HLN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Haleon (HLN) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be overvalued. The current stock price of $9.82 is trading 0.1% above its estimated GF Value™ of $9.81. GuruFocus considers Haleon to be Fairly Valued.

Key valuation signals for HLN:

  • Valuation Rank:
  • GF Value™: $9.81 vs. price of $9.82 (0.1% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score

Get the complete analysis for HLN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.82
Price
$9.81
GF Value